Fig. 1From: Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation studyKaplan–Meier curves for progression-free survival (PFS) (A) and stratified by clinical characteristics, including (B) brain metastasis, (C) bone metastasis, and (D) TNM stageBack to article page